Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review

Epidermolysis bullosa acquisita (EBA) is a chronic, recurrent autoimmune subepidermal bullous disease characterized by the presence of autoantibodies targeting type VII collagen -- basement membrane zone antigen. Standard therapy for EBA includes a combination of systemic corticosteroids and dapsone...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Konrad Szymański, Cezary Kowalewski, Ewelina Pietrzyk, Katarzyna Woźniak
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-07-01
coleção:	Frontiers in Immunology
Assuntos:	epidermolysis bullosa acquisita EBA rituximab infliximab IVIG inflammatory bowel diseases
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1214011/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!